<DOC>
	<DOCNO>NCT00037557</DOCNO>
	<brief_summary>To characterize safety efficacy rFIX child le 6 year age severe hemophilia B set acute bleed episode , prophylaxis , and/or surgery . This study provide opportunity systematic observation treatment rFIX child le 6 year age regardless prior FIX treatment . Younger patient exhibit different pharmacokinetic profile therefore may respond differently rFIX infusion compare old child adult . This evaluation provide data recommendation make regard rFIX dose treatment patient . Surveillance certain observation make patient treated rFIX clinical postmarketing setting perform , include inhibitor development , thrombogenicity , FIX recovery/lack effect , allergic-type manifestation , RBC agglutination . Comparisons derive publish report communication describe experience FIX product protein therapeutic general .</brief_summary>
	<brief_title>Study Evaluating rFIX ; BeneFIX Severe Hemophilia B</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>Severe hemophilia B Less 5 year age In investigator 's judgment , patient and/or caregiver compliant study procedures A currently detectable FIX inhibitor . A family history inhibitor exclude patient . Impaired liver function Impaired renal function</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Hemophilia B</keyword>
</DOC>